BioPharma Dive | Oct 29, 2026

HHS Secretary Robert F. Kennedy Jr. announced the agency will not enforce against state-licensed pharmacies, federal facilities and licensed physicians that compound six peptides, including BPC-157 and TB-500. The move came after FDA officials declined to endorse a rule calling the substances safe. The policy is the week’s biggest regulatory story and raises fresh questions about how the FDA draws the line between drugs and lawful supplement ingredients.

Nutritional Outlook | Nov 2, 2026

The analysis notes that supplements sit under a separate framework from compounded drugs, yet the interim policy could influence arguments over drug status, documentation expectations and gray-market competition. The policy is nonbinding and approves nothing. How it interacts with DSHEA’s drug exclusion clause remains unresolved.

NBC Chicago | Oct 31, 2026

The FDA announced a recall of one lot of 365 Whole Foods Market ashwagandha capsules made by Vitality Works after routine sampling found possible Salmonella contamination. The product was sold nationwide at Whole Foods and on Amazon, and no illnesses have been reported. The recall underscores manufacturers’ cGMP obligations under the framework DSHEA established.

Townhall | Oct 29, 2026

The administration is permitting some kratom product levels while keeping the most concentrated, enhanced forms prohibited under a threshold approach recommended by HHS. Critics argue industry lobbying drove the shift, and states continue to adopt their own restrictions. The episode shows how botanical products can fall in and out of supplement status as federal and state rules diverge.

NutraIngredients | Nov 2, 2026

The Southern African Botanical Products Association says South African Sceletium tortuosum has received self-affirmed GRAS status in the US as a raw material, and it is pursuing the same for a generic extract. The development highlights the continuing role of self-affirmed pathways for ingredient market access at a time when FDA is moving toward mandatory GRAS notification.

NutraIngredients | Oct 28, 2026

Italy’s health ministry classified a monacolin-free red yeast rice strain as a novel food requiring EU authorization. The ruling arrives as the European Commission moves to ban monacolins in food supplements. For US stakeholders, it illustrates how stricter overseas ingredient rules can shape global supply and the relative openness of the DSHEA framework.

NutraIngredients | Oct 28, 2026

The Unified Patent Court provisionally barred Pendulum and four online retailers from selling two probiotic products in eight European countries over a patent on treating insulin resistance. Pendulum has appealed and disputes the patent’s validity. The case shows how intellectual property can restrict supplement ingredient markets outside the US.

NutraIngredients | Oct 29, 2026

Food Supplements Europe issued guidelines on influencer marketing, citing research that found 474 potentially misleading supplement posts among more than 540,000 analyzed. The guidance stresses shared responsibility for brands and creators. The theme parallels US scrutiny of supplement claims under FDA and FTC authority.

NutraIngredients | Oct 27, 2026

The UK Advertising Standards Authority found 1,383 supplement ads that claimed to prevent, treat or cure ADHD and autism-related traits. Compliance remains low despite enforcement. The findings reinforce why disease claims remain a bright line for supplements under DSHEA and why industry credibility depends on clean marketing.